CD55 and cancer: There was no statistically significant difference in outcomes according to the presence of DAF (Supplementary Fig. S1), edoxaban administration dose (15 mg vs. 30 mg vs. 60 mg; Supplementary Fig. S2), primary cancer site (Supplementary Fig. S3), renal function (CrCl: ≤50 mL/min vs. > 50–80 mL/min vs. > 80 mL/min; Supplementary Fig. S4), body weight (≤60 kg vs. > 60 kg; Supplementary Fig. S5), and age (< 75 years vs. ≥75 years old; Supplementary Fig. S6).